Skip to content

Journal of Pharmacology and Experimental Therapeutics

ISSN 0022-3565, 1521-0103

133 papers in the library · 3,670 citations · publishing 1961-2025

Papers

Sort Most recent Most cited

Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.

Journal of Pharmacology and Experimental Therapeutics June 2007 Marcello Solinas, Maria Scherma, Gianluigi Tanda et al.

Systemic administration of the main active ingredient in cannabis, Delta9-tetrahydrocannabinol (THC), alters extracellular levels of acetylcholine in several brain areas, suggesting an involvement of the cholinergic system in the psychotropic effects of cannabis. Here, we investigated whether drugs acting at either nicotinic or muscarinic receptors can modulate the discriminative effects of...

Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.

Journal of Pharmacology and Experimental Therapeutics June 2007 Pablo R Moya, Kelly A Berg, Manuel A Gutiérrez-Hernandez et al.

2,5-Dimethoxy-4-substituted phenylisopropylamines and phenethylamines are 5-hydroxytryptamine (serotonin) (5-HT)(2A/2C) agonists. The former are partial to full agonists, whereas the latter are partial to weak agonists. However, most data come from studies analyzing phospholipase C (PLC)-mediated responses, although additional effectors [e.g., phospholipase A(2) (PLA(2))] are associated with...

The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.

Journal of Pharmacology and Experimental Therapeutics April 2007 Marcello Solinas, Gianluigi Tanda, Zuzana Justinova et al.

Anandamide is an endogenous ligand for brain cannabinoid CB(1) receptors, but its behavioral effects are difficult to measure due to rapid inactivation. Here we used a drug-discrimination procedure to test the hypothesis that anandamide, given i.v. or i.p., would produce discriminative effects like those of delta-9-tetrahydrocannabinol (THC) in rats when its metabolic inactivation was...

Salvinorin A: allosteric interactions at the mu-opioid receptor.

Journal of Pharmacology and Experimental Therapeutics February 1, 2007 Richard B Rothman, Daniel L Murphy, Heng Xu et al. 75 citations

Salvinorin A [(2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester] is a hallucinogenic kappa-opioid receptor agonist that lacks the usual basic nitrogen atom present in other known opioid ligands. Our first published studies indicated that Salvinorin A weakly inhibited mu-receptor binding, and...

DOI: 10.1124/jpet.106.113167 (opens in new tab) Full text (opens in new tab) Salvinorin a Hallucinogen Psychoactive compound Mu-opioid receptor +9

5-Hydroxytryptamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide.

Journal of Pharmacology and Experimental Therapeutics February 2007 Paul J Gresch, Robert J. Barrett, Elaine Sanders‐bush et al.

d-Lysergic acid diethylamide (LSD), an indoleamine hallucinogen, produces profound alterations in mood, thought, and perception in humans. The brain site(s) that mediates the effects of LSD is currently unknown. In this study, we combine the drug discrimination paradigm with intracerebral microinjections to investigate the anatomical localization of the discriminative stimulus of LSD in rats....

Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

Journal of Pharmacology and Experimental Therapeutics 2007 Eduardo R Butelman, Marek Mandau, Kevin Tidgewell et al. 64 citations

This study focused on the in vivo effects of the kappa-opioid hallucinogen salvinorin A, derived from the plant Salvia divinorum. The effects of salvinorin A (0.0032-0.056 mg/kg i.v.) were studied in a neuroendocrine biomarker assay of the anterior pituitary hormone prolactin in gonadally intact, adult male and female rhesus monkeys (n = 4 each). Salvinorin A produced dose- and time-dependent...

DOI: 10.1124/jpet.106.112417 (opens in new tab) Full text (opens in new tab) Plant-derived compound Hallucinogen Kappa-opioid agonist Opioid antagonist +15

Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.

Journal of Pharmacology and Experimental Therapeutics August 1, 2006 Michael Ansonoff, Jiwen Zhang, Traci A Czyzyk et al. 101 citations

Salvia divinorum is a natural occurring hallucinogen that is traditionally used by the Mazatec Indians of central Mexico. The diterpene salvinorin A was identified as an active component of S. divinorum over 20 years ago, but only recently has biochemical screening indicated that a molecular target of salvinorin A in vitro is the kappa-opioid receptor. We have examined whether salvinorin A, the...

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

Journal of Pharmacology and Experimental Therapeutics July 2006 Sachin Patel, Cecilia J. Hillard

Extracts of Cannabis sativa have been used for their calming and sedative effects for centuries. Recent developments in drug discovery have suggested that modulation of neuronal endogenous cannabinoid signaling systems could represent a novel approach to the treatment of anxiety-related disorders while minimizing the adverse effects of direct acting cannabinoid receptor agonists. In this study,...

Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

Journal of Pharmacology and Experimental Therapeutics January 2006 William A Carlezon, Cécile Béguin, Jennifer A DiNieri et al.

Endogenous opioids seem to play a critical role in the regulation of mood states. For example, there is accumulating evidence that stimulation of kappa-opioid receptors, upon which the endogenous opioid dynorphin acts, can produce depressive-like behaviors in laboratory animals. Here we examined whether systemic administration of salvinorin A (SalvA), a potent and highly selective kappa-opioid...

Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia.

Journal of Pharmacology and Experimental Therapeutics January 2006 João Paulo Capela, Andreas Meisel, Artur Reis Abreu et al.

3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") is a widely abused, psychoactive recreational drug. There is growing evidence that the MDMA neurotoxic profile may be highly dependent on both its hepatic metabolism and body temperature. Metabolism of MDMA involves N-demethylation to 3,4-methylenedioxyamphetamine (MDA), which is also a drug of abuse. MDMA and MDA are O-demethylenated to...

Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.

Journal of Pharmacology and Experimental Therapeutics April 2005 Douglas C. Jones, Christine L. Duvauchelle, Aiko Ikegami et al.

The selective serotonergic neurotoxicity of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) depends on their systemic metabolism. We have recently shown that inhibition of brain endothelial cell gamma-glutamyl transpeptidase (gamma-GT) potentiates the neurotoxicity of both MDMA and MDA, indicating that metabolites that are substrates for this enzyme...

Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.

Journal of Pharmacology and Experimental Therapeutics October 2004 Douglas C. Jones, Serrine S. Lau, Terrence J. Monks

3,4-Methylenedioxyamphetamine (MDA) and 3,4-methyl-enedioxymethamphetamine (MDMA, ecstasy) are widely abused amphetamine derivatives that target the serotonin system. The serotonergic neurotoxicity of MDA and MDMA seems dependent on their systemic metabolism. 5-(Glutathion-S-yl)-alpha-methyldopamine [5-(GSyl)-alpha-MeDA] and 2,5-bis(glutathion-S-yl)-alpha-methyldopamine...

Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Journal of Pharmacology and Experimental Therapeutics March 1, 2004 Charles Chavkin, Sumit Sud, Wenzhen Jin et al. 212 citations

The diterpene salvinorin A from Salvia divinorum has recently been reported to be a high-affinity and selective kappa-opioid receptor agonist (Roth et al., 2002). Salvinorin A and selected derivatives were found to be potent and efficacious agonists in several measures of agonist activity using cloned human kappa-opioid receptors expressed in human embryonic kidney-293 cells. Thus, salvinorin...

Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics

Journal of Pharmacology and Experimental Therapeutics June 18, 2003 Jordi Riba, Marta Valle, Gloria Urbano et al. 383 citations

The effects of the South American psychotropic beverage ayahuasca on subjective and cardiovascular variables and urine monoamine metabolite excretion were evaluated, together with the drug's pharmacokinetic profile, in a double-blind placebo-controlled clinical trial. This pharmacologically complex tea, commonly obtained from Banisteriopsis caapi and Psychotria viridis, combines...

In Vivo Neurobiological Effects of Ibogaine and Its O-Desmethyl Metabolite, 12-Hydroxyibogamine (Noribogaine), in Rats

Journal of Pharmacology and Experimental Therapeutics May 1, 2001 Michael H. Baumann, Richard B Rothman, John Pablo et al. 69 citations

Ibogaine is a naturally occurring compound with purported antiaddictive properties. When administered to primates, ibogaine is rapidly o-demethylated to form the metabolite 12-hydroxyibogamine (noribogaine). Peak blood levels of noribogaine exceed those of ibogaine, and noribogaine persists in the bloodstream for at least 1 day. Very few studies have systematically evaluated the neurobiological...

DOI: 10.1016/s0022-3565(24)29567-7 (opens in new tab) Serotonin Pharmacology Nucleus accumbens Microdialysis +7

Mechanisms of N-methyl-D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons.

Journal of Pharmacology and Experimental Therapeutics July 1, 2000 Cheng Z Wang, Joel A. Kaufmann, Monica G. Sanchez-Ross et al.

Chronic administration of phencyclidine (PCP) to rats has been demonstrated to produce a sensitized locomotor response to PCP challenge that is associated with apoptotic cell death and an up-regulation of the N-methyl-D-aspartate (NMDA) receptor. To determine the underlying mechanisms, dissociated forebrain cultures were treated for 2 days with 3 microM PCP. After washout of PCP, NMDA was added...

Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism.

Journal of Pharmacology and Experimental Therapeutics April 1, 2000 G. Duncan, S. Miyamoto, Jeremy N Leipzig et al.

The ability of subanesthetic doses of N-methyl-D-aspartate (NMDA) antagonists to induce positive, negative, and cognitive schizophrenia-like symptoms suggests that reduced NMDA receptor function may contribute to the pathophysiology of schizophrenia. An increasing body of evidence indicates that antipsychotic drugs, especially those with "atypical" properties, can antagonize the effects of NMDA...

Characterization of MK-801-induced behavior as a putative rat model of psychosis.

Journal of Pharmacology and Experimental Therapeutics September 1, 1999 Peter Andiné, Nina Widermark, R. Axelsson et al.

The objective of this study was to characterize the behavior induced by the N-methyl-D-aspartate receptor antagonist MK-801 (dizocilpine maleate) in rats as a model of psychosis. The temporal profile, dose dependence, age, and sex differences of the behavior are described. A gas chromatographic method for the analysis of MK-801 in plasma and brain was developed. Female rats showed 4 to 10 times...

Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Journal of Pharmacology and Experimental Therapeutics July 1, 1999 M. Mas, M. Farré, Rafael de la Torre et al. 362 citations

The cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") were assessed in a double-blind, randomized, crossover, and controlled (placebo and amphetamine) clinical trial. Eight men with experience in the recreational use of MDMA participated in four 10-h experimental sessions with a 1-week washout period. Single oral doses of 125...

Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine

Journal of Pharmacology and Experimental Therapeutics 1999 John Denis Fryer, Ronald J. Lukas 283 citations

Nicotinic acetylcholine receptors (nAChR) are diverse members of the neurotransmitter-gated ion channel superfamily and play critical roles in chemical signaling throughout the nervous system. The present study establishes the acute functional effects of bupropion, phencyclidine, and ibogaine on two human nAChR subtypes. Function of muscle-type nAChR (alpha1 beta gamma delta) in TE671/RD cells...

DOI: 10.1016/s0022-3565(24)37928-5 (opens in new tab) Nicotinic acetylcholine receptor Phencyclidine Pharmacology Nicotinic agonist +7

LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.

Journal of Pharmacology and Experimental Therapeutics September 1, 1996 Gerard J. Marek, George K. Aghajanian

Correlations between 5-hydroxytryptamine (5-HT) receptor binding affinities and human hallucinogenic potency have suggested that 5-HT2 receptors mediate the hallucinogenic effects of lysergic acid diethylamide (LSD) and phenethylamine hallucinogens. Electrophysiological studies have suggested that a subpopulation of gamma-aminobutyric acid (GABA)ergic interneurons in layer III of the rat...

Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat.

Journal of Pharmacology and Experimental Therapeutics July 1, 1996 Jessica E. Malberg, K E Sabol, Lewis S. Seiden

The substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA) has been shown to be neurotoxic to serotonin (5HT) terminals in the rat, and rat body temperature (TEMP) has been shown to affect this neurotoxicity. This study looked at the effect on CORE TEMP of three drugs that protect against MDMA neurotoxicity in the rat. Male Holtzmann rats were injected with a control saline (SAL)...

DOI: 10.1016/s0022-3565(25)20131-8 (opens in new tab) Animals Rats N-methyl-3,4-methylenedioxyamphetamine Fluoxetine +5

Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations.

Journal of Pharmacology and Experimental Therapeutics February 1, 1996 K E Sabol, R Lew, J B Richards et al.

The effects of a high dose methylenedioxymethamphetamine (MDMA) regimen on the serotonin (5-HT) system were evaluated over a 52-wk period. MDMA was administered to rats (20 mg/kg) 8 times at 12-hr intervals. Tissue concentrations of dopamine (DA) and 5-HT, and synaptosomal uptake of 3H-5-HT and 3H-DA were measured at 2, 8, 16, 32 or 52 wk posttreatment. Synaptosomal uptake of 3H-5-HT...

DOI: 10.1016/s0022-3565(25)12371-9 (opens in new tab) Synaptosomes Animals Rats, sprague-dawley Dopamine +5

Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies.

Journal of Pharmacology and Experimental Therapeutics February 1, 1996

In our study, age-matched Holtzman Sprague-Dawley rats (275-300 g) received injections with either saline (0.9%) or 3,4-methylenedioxymethamphetamine (MDMA; 20 mg/kg free base, s.c) twice daily for 4 days and allowed to recover for 2, 8, 16, 32 and 52 wk after the final injection before death. Radioligand binding studies with 125I-RTI-55 to dopamine uptake sites in striatal homogenates showed...

A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA.

Journal of Pharmacology and Experimental Therapeutics February 1, 1996 R Young, Richard A Glennon

1-(3,4-Methylenedioxyphenyl)-2-aminopropane (MDA) produces an effect in humans that is somewhat similar to both a hallucinogen and a central stimulant. We have previously shown that R(-)-MDA but not S(+)-MDA produces a stimulus effect in animals similar to that of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), whereas S(+)-MDA but not R(-)-MDA produces a stimulus effect...

DOI: 10.1016/s0022-3565(25)12311-2 (opens in new tab) Animals Rats, sprague-dawley 3,4-methylenedioxyamphetamine Hallucinogens +5